These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 626991)

  • 1. Antileukemia therapy and toxicology studies in mice with beta-2'-deoxythioguanosine.
    Momparier RL; Higgins G; Siegel SE; Rucker N; Momparier L; Gonzales F
    Cancer Treat Rep; 1978 Jan; 62(1):135-7. PubMed ID: 626991
    [No Abstract]   [Full Text] [Related]  

  • 2. [Modulation of the antitumor activity of 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosoure a by O(6)-methyl-2'-deoxyguanosine--a new inhibitor of O(6)-alkylguanine-DNA-alkyltransferase].
    Dederer LIu; Sokolova IS; Bakhmedova AA; Miniker TD; Mel'nik SIa; Gorbacheva LB
    Biokhimiia; 1995 Sep; 60(9):1521-9. PubMed ID: 8562657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The synthesis and anti-neoplastic activity of N2-isobutyryl-2'-deoxyguanosine-N7-cyanoborane derivatives.
    Sood A; Shaw BR; Spielvogel BF; Hall ES; Chi LK; Hall IH
    Pharmazie; 1992 Nov; 47(11):833-8. PubMed ID: 1492112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia.
    Higgins GR; Jamin DC; Shore NA; Momparler R; Hartman G; Siegel SE
    Cancer Treat Rep; 1985 Jun; 69(6):699-701. PubMed ID: 3860294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemia L1210 therapy trials with antileukemia serum and Bacillus Calmette-Guérin.
    Reif AE; Kim CA
    Cancer Res; 1971 Nov; 31(11):1606-12. PubMed ID: 5001090
    [No Abstract]   [Full Text] [Related]  

  • 6. Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine.
    Semon JH; Grindey GB
    Cancer Res; 1978 Sep; 38(9):2905-11. PubMed ID: 679199
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral and parenteral activity of 2,2'-anhydro-1- -D-arabinofuranosyl-5-fluorocytosine against both intraperitoneally and intracerebrally inoculated mouse leukemia.
    Fox JJ; Falco EA; Wempen I; Pomeroy D; Dowling MD; Burchenal JH
    Cancer Res; 1972 Oct; 32(10):2269-72. PubMed ID: 4673145
    [No Abstract]   [Full Text] [Related]  

  • 8. Lack of activity of beta-2'-deoxythioguanosine against two tumors resistant to 6-thioguanine.
    Nelson JA; Kuhns JN; Carpenter JW
    Cancer Res; 1975 May; 35(5):1372-4. PubMed ID: 1168098
    [No Abstract]   [Full Text] [Related]  

  • 9. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 10. Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with adriamycin and cyclophosphamide.
    Scheving LE; Burns ER; Pauly JE; Halberg F
    Cancer Res; 1980 May; 40(5):1511-5. PubMed ID: 7370988
    [No Abstract]   [Full Text] [Related]  

  • 11. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.
    Cass CE; Au-Yeung TH
    Cancer Res; 1976 Apr; 36(4):1486-91. PubMed ID: 944095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of DL-threo-beta-fluoroasparagine against human leukemia cells in culture and L1210 cells in DBA mice.
    Stern AM; Abeles RH; Tashjian AH
    Cancer Res; 1984 Dec; 44(12 Pt 1):5614-8. PubMed ID: 6498822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of leukemia L1210 in mice with 1-beta-D-arabinofuranosylcytosine hydrochloride. II. Effectiveness against intracerebrally and subcutaneously inoculated leukemic cells.
    Kline I; Venditti JM; Tyrer DD; Mantel N; Goldin A
    Cancer Res; 1966 Sep; 26(9):1930-7. PubMed ID: 5924958
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules.
    Kline I; Venditti JM; Tyrer DD; Goldin A
    Cancer Res; 1966 May; 26(5):853-9. PubMed ID: 5936445
    [No Abstract]   [Full Text] [Related]  

  • 15. Antitumor effect and mode of action of 1-beta-D-arabinofuranosylcytosine 5'-phosphate in leukemia L1210.
    Schrecker AW; Goldin A
    Cancer Res; 1968 Apr; 28(4):802-3. PubMed ID: 5649067
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
    Cass CE; Muzik H; Paterson AR
    Cancer Res; 1975 May; 35(5):1187-93. PubMed ID: 1120308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue of thymidine cytotoxicity in L1210 ascites by elevated endogenous levels of deoxycytidine.
    Egan EM; Sargent L; Rosowsky A; Kufe DW
    Cancer Treat Rep; 1981; 65(9-10):853-60. PubMed ID: 7273018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
    Klubes P; Cerna I
    Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of L1210 leukemia to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea plus 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside).
    Roberts D; Peck C; Hilliard S; Karas JG
    Cancer Res; 1981 Oct; 41(10):3891-5. PubMed ID: 7284998
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
    Brockman RW; Cheng YC; Schabel FM; Montgomery JA
    Cancer Res; 1980 Oct; 40(10):3610-5. PubMed ID: 6254636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.